Vulnerability to involuntary movements over a lifetime trajectory of schizophrenia approaches 100%, in association with executive (frontal) dysfunction

Schizophrenia Research

Volumn 49, Issue 1-2, 2001, Pages 79-87

  Quinn, John ^a   Meagher, David ^b   Murphy, Patrice ^c   Kinsella, Anthony ^d   Mullaney, James ^b   Waddington, John L ^a,e  

^a St Davnet's Hospital   (Ireland)

^b St Ita's Hospital   (Ireland)

^c St Loman's Hospital   (Ireland)

^d DUBLIN INSTITUTE OF TECHNOLOGY   (Ireland)

^e ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Cognitive dysfunction; Executive dyscontrol; Involuntary movements; Schizophrenia; Tardive dyskinesia

Indexed keywords

CHLORPROMAZINE; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; BODY REGIONS; COGNITION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; INVOLUNTARY MOVEMENT; LONG TERM CARE; LONGEVITY; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DYSKINESIA, DRUG-INDUCED; FEMALE; FRONTAL LOBE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR DISORDERS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 0035870925     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(99)00220-0     Document Type: Article

References (44)

1. Diagnostic and Statistical Manual of Mental Disorders. fourth ed. 1994;American Psychiatric Association, Washington, DC.
2. Baldessarini R.J., Cole J.O., Davis J.M., Gardos G., Preskorn S.H., Tarsy D. Tardive Dyskinesia. 1980;American Psychiatric Association, Washington, DC.
3. Brown K.W., White T., Palmer D. Movement disorders and psychological tests of frontal lobe function in schizophrenic patients. Psychol. Med. 22:1992;69-77.
4. Chatterjee A., Chakos M., Koreen A., Geisler S., Sheitman B., Woerner M., Kane J., Alvir J., Lieberman J.A. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am. J. Psychiatry. 152:1995;1724-1729.
5. Cooper S.J., Doherty M.M., Waddington J.L. Tardive dyskinesia in schizophrenia and its association with treatment, symptomatology and cognitive function. Eur. Neuropsychopharmacol. 3:1993;405-406.
6. Davidson M., Harvey P.D., Powchik P., Parrella M., White L., Knobler H.Y., Losonczy M.F., Keefe R.S.E., Katz S., Frecksa E. Severity of symptoms in chronically institutionalised geriatric schizophrenia patients. Am. J. Psychiatry. 152:1995;197-207.
7. Elliott R., McKenna P.J., Robbins T.W., Sahakian B.J. Neuropsychological evidence for frontostriatal dysfunction in schizophrenia. Psychol. Med. 25:1995;619-630.
8. Fenn D.S., Moussaoui D., Hoffman W.F., Kadri N., Bentounssi B., Tilane A., Khomeis M., Casey D.E. Movements in never-medicated schizophrenics: a preliminary study. Psychopharmacology. 123:1996;206-210.
9. Fenton W.S., Wyatt R.J., McGlashan T.H. Risk factors for spontaneous dyskinesia in schizophrenia. Arch. Gen. Psychiatry. 51:1994;643-650.
10. Folstein M.F., Folstein S.E., McHugh P.R. 'Mini-Mental State': a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:1975;189-198.
11. Frith C.D. Schizophrenia: functional imaging and cognitive abnormalities. Lancet. 346:1995;615-620.
12. Gervin M., Browne S., Lane A., Clarke M., Waddington J.L., Larkin C., O'Callaghan E. Spontaneous abnormal involuntary movements in first episode schizophrenia and schizophreniform disorder: baseline rate in a sample from an Irish catchment area population. Am. J. Psychiatry. 155:1998;1202-1206.
13. Graybiel A.M. The basal ganglia and cognitive pattern generators. Schizophr. Bull. 23:1997;459-469.
14. Green J.F., King D.J. Cognitive functioning in schizophrenia: effects of drug treatments. CNS Drugs. 5:1996;382-398.
15. Heckers S. Neuropathology of schizophrenia: cortex, thalamus, basal ganglia and neurotransmitter-specific projection systems. Schizophr. Bull. 23:1997;403-421.
16. Jeste D.V., Wyatt R.J. Understanding and Treating Tardive Dyskinesia. 1982;Guilford Press, New York.
17. Kane J.M., Jeste D.V., Barnes T.R.E., Casey D.E., Cole J.O., Davis J.M., Gualtieri C.T., Schooler N.R., Sprague R.L., Wettstein R.M. Tardive Dyskinesia. 1992;American Psychiatric Association, Washington, DC.
18. Kay S.R. Positive and Negative Syndromes in Schizophrenia. 1991;Brunner/Mazel, New York.
19. Kay S.R., Fisbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13:1987;261-276.
20. McCreadie R.G., Ohaeri J.U. Movement disorder in never and minimally treated Nigerian schizophrenic patients. Br. J. Psychiatry. 164:1994;184-189.
21. McCreadie R.G., Thara R., Kamath S., Padmavathy R., Latha S., Mathrubootham N., Menon M.S. Abnormal movements in never-medicated Indian patients with schizophrenia. Br. J. Psychiatry. 168:1996;221-226.
22. Meagher D., Quinn J., Murphy P., Kinsella A., Mullaney J., Waddington J.L. Duration of initially untreated psychosis predicts selectively the 'psychomotor poverty' factor in schizophrenia. Schizophr. Res. 29:1998;37.
23. Middleton F.A., Strick P.L. Anatomical evidence for cerebellar and basal ganglia involvement in higher cognitive function. Science. 266:1994;458-461.
24. Morice R., Delahunty A. Frontal/executive impairments in schizophrenia. Schizophr. Bull. 22:1996;125-137.
25. Mortimer A.M. Cognitive function in schizophrenia - do neuroleptics make a difference? Pharmacol. Biochem. Behav. 56:1997;789-795.
26. Abnormal involuntary movement scale. Guy W. Early Clinical Drug Evaluation Unit Assessment Manual. 1976;534-537 Department of Health and Human Services, Rockville, MD.
27. Owens D.G.C., Johnstone E.C., Frith C.D. Spontaneous involuntary disorders of movement. Arch. Gen. Psychiatry. 39:1982;452-461.
28. Pantelis C., Barnes T.R.E., Nelson H.E. Is the concept of frontal-subcortical dementia relevant to schizophrenia? Br. J. Psychiatry. 16:1992;442-460.
29. Paulsen J.S., Caligiuri M.P., Palmer B., McAdams L.A., Jeste D.V. Risk factors for orofacial and limb-truncal tardive dyskinesia in older patients: a prospective longitudinal study. Psychopharmacology. 123:1996;307-314.
30. Puri B.K., Barnes T.R.E., Chapman M.J., Hutton S.B., Joyce E.M. Spontaneous dyskinesia in first episode schizophrenia. J. Neurol. Neurosurg. Psychiatry. 66:1999;76-78.
31. Royall D.R., Mahurin R.K., Gray K.F. Bedside assessment of executive cognitive impairment: the executive interview. J. Am. Geriatr. Soc. 40:1992;1221-1226.
32. Royall D.R., Mahurin R.K., True J.E., Anderson B., Brock I.P., Freeburger L., Miller A. Executive impairment among the functionally dependent: comparisons between schizophrenic and elderly subjects. Am. J. Psychiatry. 150:1993;1813-1819.
33. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry. 39:1982;486-487.
34. Scully P.J., Coakley G., Kinsella A., Waddington J.L. Executive (frontal) dysfunction and negative symptoms in schizophrenia: apparent gender differences in 'static' v. 'progressive' profiles. Br. J. Psychiatry. 171:1997;154-158.
35. Scully P.J., Coakley G., Kinsella A., Waddington J.L. Psychopathology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated versus subsequently treated psychosis in chronic schizophrenia. Psychol. Med. 27:1997;1303-1310.
36. Smith E.E., Jonides J. Storage and executive processes in the frontal lobes. Science. 283:1999;1657-1661.
37. Verdoux H., Magnin E., Bourgeois M. Neuroleptic effects on neuropsychological test performance in schizophrenia. Schizophr. Res. 14:1995;133-139.
38. Waddington J.L. Schizophrenia, affective psychoses and other disorders treated with neuroleptic drugs: the enigma of tardive dyskinesia, its neurobiological determinants, and the conflict of paradigms. Int. Rev. Neurobiol. 31:1989;297-353.
39. Waddington J.L. Psychopathological and cognitive correlates of tardive dyskinesia in schizophrenia and other disorders treated with neuroleptic drugs. Weiner W.J., Lang A.E. Behavioral Neurology of Movement Disorders. 1995;211-229 Raven Press, New York.
40. Waddington J.L., Youssef H.A. The lifetime outcome and involuntary movements of schizophrenia never treated with neuroleptic drugs. Br. J. Psychiatry. 15:1990;106-108.
41. Waddington J.L., O'Callaghan E., Buckley P., Madigan C., Redmond O., Stack J.P., Kinsella A., Larkin C., Ennis J.T. Tardive dyskinesia in schizophrenia: relationship to minor physical anomalies, frontal lobe dysfunction and cerebral structure on magnetic resonance imaging. Br. J. Psychiatry. 167:1995;41-44.
42. Waddington J.L., Youssef H.A., Kinsella A. Sequential cross-sectional and 10-year prospective study of severe negative symptoms in relation to duration of initially untreated psychosis in chronic schizophrenia. Psychol. Med. 25:1995;847-857.
43. Waddington J.L., Youssef H.A., Dolphin C., Kinsella A. Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Arch. Gen. Psychiatry. 44:1987;907-912.
44. Weinberger D.R. Schizophrenia: from neuropathology to neurodevelopment. Lancet. 346:1995;552-557.